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Abstract
Background: Although a score of less than 7 for the 17-item Hamilton Depression Rating Scale (HAM-D17) has
been widely adopted to define remission of depression, a full recovery from depression is closely related to the
patient’s quality of life as well. Accordingly, we re-evaluated this definition of remission using HAM-D17 in
comparison with the corresponding score for health-related quality of life (HRQOL) measured by the SF-36.
Methods: Using the data for depressive patients reported by GlaxoSmithKline K.K. (Study No. BRL29060A/863) in a
post-marketing observational study of paroxetine, with a sample size of n = 722, multivariate logistic regression was
performed with the HAM-D17 score as a dependent variable and with each of the eight domain scores of HRQOL
(from the SF-36) transformed into a binominal form according to the national standard value for Japan. Then, area
under curve of receiver operating characteristic analyses were conducted. Based on the obtained results, a multivariate
analysis was performed using the HAM-D17 score in a binomial form with HAM-D17 as a dependent variable and with
each of the eight HRQOL domain scores (SF-36) as binominalized independent variables.
Results: A cutoff value for the HAM-D17 score of 5 provided the maximum ROC-AUC at “0.864.” The significantly
associated scores of the eight HRQOL domains (SF-36) were identified for the HAM-D17 cutoff values of ≥5 and ≤4.
The scores for physical functioning (odds ratio, 0.473), bodily pain (0.557), vitality (0.379), social functioning (0.540),
role-emotion (0.265), and mental health (0.467) had a significant negative association with the HAM-D17 score
(p < 0.05), and HRQOL domain scores for HAM-D17≥ 5 were significantly lower compared with those for HAM-D17≤ 4.
Conclusions: A cutoff value for HAM-D17 of less than or equal to 4 was the best candidate for indicating remission of
depression when the recovery of HRQOL is considered. Restoration of social function and performance should be
considered equally important in assessing the adequacy of treatment for patients with depression.
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Background
Guidelines for the treatment of major depressive
disorders recommend that the primary therapeutic goal
is to achieve remission in the acute phase of therapy
[1, 2]. Traditionally, for the assessment of depression, the
17-item Hamilton Depression Rating Scale (HAM-D17)
has been considered the gold standard [3, 4] with remis-
sion of depression indicated by a score of ≤7 [5–7]. How-
ever, depressive disorders also impair health-related
quality of life (HRQOL) [8, 9]. Practically, it is widely rec-
ognized that both remission of depression symptoms and
recovery of HRQOL are important in clinical treatment
and research [10].
GlaxoSmithKline K.K. conducted a post-marketing
clinical study to evaluate HRQOL using the Medical
Outcome Study 36-Item Short-Form Health Survey scale
(SF-36) in Japanese patients with depression treated with
paroxetine. Overall, 12 weeks of treatment with paroxe-
tine (20–40 mg/d) yield a significant improvement in
both depression symptoms (HAM-D17) and HRQOL
(SF-36). An investigation of the relationship between
HAM-D17 scores and SF-36 scores was performed, and
patients with higher degrees of improvement in depres-
sion symptoms tended to show higher degrees of im-
provement in HRQOL, as reported in an article related
to the present study [11]. In the two SF-36 mental health
dimensions of social functioning (SF) and role-emotional
(RE), obtained scores were close to the level of the Japa-
nese national norm when patients achieved remission of
depression symptoms [12], which suggests a strong asso-
ciation between the remission of depression symptoms
and recovery in HRQOL.
A HAM-D17 score of ≤7 was used to define remission
of depression symptoms in the above post-marketing
clinical study. While a HAM-D17 score of ≤7 has been
widely adopted in clinical trials and research, little data
support this threshold score from the perspective of
HRQOL. Therefore, it is important to confirm the valid-
ity of this threshold score for remission of depression
symptoms with respect to HRQOL for alignment with
the primary therapeutic goal in the acute phase of
therapy.
In this study, we investigated which symptom severity
(HAM-D17) score was equivalent to recovery in
HRQOL (SF-36 score) as indicators of remission.
Through the analysis of raw data obtained from a post-
marketing clinical study, we re-evaluated the definition
of remission of depression to examine the validity and
consistency of the existing definition (i.e., HAM-D17
score of ≤7) with respect to HRQOL.
Our specific objectives were as follows: (1) to investi-
gate this definition of remission by comparison with the
recovery in HRQOL for validity and consistency, (2) to
examine the association of HRQOL domain scores (SF-
36) with the severity of depression symptoms (HAM-
D17 scores), and (3) to compare the depression symp-
toms (HAM-D 17 scores) of remitters (responders) and
non-remitters (non-responders) using the recalculated
cutoff score obtained in the present trial.
Methods
Data source and data management
Data sources for analysis
Raw data were obtained from a post-marketing clinical
study of paroxetine in patients with depression or those
experiencing depressive episodes, which included an
evaluation of improvement by paroxetine of HRQOL
(Study No. BRL29060A/863) [11, 13].
Data management
Raw data were obtained as anonymized patient data
from GlaxoSmithKline K.K. Data were used and managed
in compliance with a “Datasharing Agreement” with and
authorized by GlaxoSmithKline K.K.
Study design
This study is a reanalysis of the raw data from a post-
marketing clinical study of paroxetine in patients with
depression or those experiencing depressive episodes,
which included an evaluation of improvement by parox-
etine of HRQOL (Study No. BRL29060A/863).
Demographic and clinical characteristics of patients
Height, weight, age, gender, onset of first depression or
depressive episode, duration of the current episode,
number of depressive episodes, depression diagnosis
[14], past medical history, concurrent illness, treatment
history, concurrent use of drugs, concurrent use of non-
drug treatment (i.e., electroconvulsive therapy and cog-
nitive behavioral therapy), comorbid anxiety disorders
assessed by the Mini International Neuropsychiatric
Interview (panic disorder, social anxiety disorder, obses-
sive-compulsive disorder, generalized anxiety disorder,
posttraumatic stress disorder), dosing, and duration of
paroxetine were evaluated.
Efficacy
Total score on HAM-D17, score on each item of HAM-
D17, state score and trait score on the State-Trait
Anxiety Inventory (STAI) [15].
Health outcome
The physical component summary (PCS) score on the
SF-36 physical health dimension is composed of physical
functioning (PF), role physical (RP), bodily pain (BP),
and general health perceptions (GH).
Sawamura et al. Health and Quality of Life Outcomes  (2018) 16:14 Page 2 of 8
The mental component summary (MCS) score on the
SF-36 mental health dimension is composed of vitality
(VT), SF, RE, and mental health (MH).
Data analysis
Primary analysis
1) The scatter plot of each individual patient’s pairwise
co-ordinates between HAM-D17 score and score on
each HRQOL (SF-36) dimension was drawn. Then, the
ability of HAM-D17 to identify patients who are in
remission according to the recovery in HRQOL across
the range of HAM-D17 cutoff scores by conducting re-
ceiver operating characteristic (ROC) analyses was ex-
amined. The HAM-D17 score showing the maximal
level of agreement with the recovery in HRQOL was de-
termined as the cutoff score of HAM-D17 for remission.
Secondary analysis
2) The cutoff value of HAM-D17 providing the maximal
ROC-AUC was converted to a binominal form of “0 or 1.”
A logistic multivariate analysis with HAM-D17 as the
dependent variable and each of the eight HRQOL do-
mains (SF-36) as binominalized independent variables was
conducted to identify the relationship between them being
associated with remitters (responders) or non-remitters
(non-responders) defined using the HAM-D17 scores.
3) Mann-Whitney U tests were conducted to com-
pare the domain subscores of HRQOL (SF-36) (PF,
RP, BP, GH, VT, SF, RE, MH, PCS, and MCS) and
STAI (the State Anxiety Scale and the Trait Anxiety
Scale) between remitters (responders) or non-remitters
(non-responders) using the recalculated cutoff score
obtained in the present trial.
We used SPSS for Windows Version 20 [16] and Stata
Release 13.0 [17] for statistical analysis and Microsoft
Excel 2003 [18] for plotting the graph.
Results
Patients treated with paroxetine (maximum dose of 20–
40 mg/d) were assessed over 12 weeks (0, 4, 8, and
12 weeks, where “0 week” means the subject dropped
from the study before week 4 for any reason). The sam-
ple number (n = 722) for analysis included assessments
at all time points for participating patients (n = 217).
The scatter plots between HAM-D17 and PCS and MCS
are shown in Figs. 1 and 2. For the sample of n = 722, a
multivariate logistic regression was performed with the
score of HAM-D17 as a dependent variable and each of
the eight domain scores of HRQOL (SF-36) as
y = -0.4162x + 52.888
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Fig. 1 Scatter plot between HAM-D17 and PCS scores
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independent variables (converted into binominal form as
“0 or 1” according to the national standard value for
Japan). By assigning the different integers of the HAM-
D17 scores as cutoff values, ROC analyses were con-
ducted and area under curve of ROC (ROC-AUC) was
calculated (Table 1). A cutoff value of 5 for HAM-D17
provided the maximum ROC-AUC as “0.864.” After con-
verting this cutoff score of HAM-D17 into the binom-
inal form of “0 or 1” for HAM-D17 of ≥5 and ≤4, a
multivariate logistic regression analysis with HAM-D17
as the dependent variable and each of the eight HRQOL
domain scores (SF-36) as binominalized independent
variables was performed. Then, the significantly associ-
ated scores of the eight HRQOL domains (SF-36) were
identified (Table 1). Specifically, the six subscores of PF
(odds ratio, 0.473), BP (0.557), VT (0.379), SF (0.540),
RE (0.265), and MH (0.467) were negatively associated
with HAM-D17. The Spearman’s ρ of the HRQOL sub-
scores with HAM-D17 are presented in Table 2. All
HRQOL subscores were negatively correlated with the
HAM-D17 scores. On performing Mann-Whitney U
tests, it was observed that all respective subscores of
HRQOL at HAM-D17 ≤ 4 are significantly higher than
those at HAM-D17 ≥ 5, and State/Trait-Anxiety of
STAI for HAM-D17 ≤ 4 were significantly lower than
those for HAM-D17 ≥ 5 (Tables 3 and 4).
Discussion
As is well known, severe depression often causes severe
impairment of quality of life in patients with depression.
In the present study, a cutoff value of 4 or lower (≤4) on
HAM-D17 provided the maximal ROC-AUC or maximal
level of agreement with HRQOL recovery. At this cutoff
value, six subscores of HRQOL (SF-36), namely PF and
BP (in the physical health dimension) and VT, SF, RE,
and MH (in the mental health dimension), were
identified with significantly negative association with the
HAM-D17 scores around 4–5 points. This result was
consistent with an existing report, which states that SF
and RE scores return to close to the level of the Japanese
national norm in Japanese patients with depression who
are remitters [12]. The significant relation of BP with
HAM-D17 was understandable because depression with
pain often harms a patient’s QOL, and alleviation of pain
is one of primary symptoms to be ameliorated in pa-
tients with depression.
Since 1991, a score of ≤7 has been a consensus in pre-
vious reports on the HAM-D17 cutoffs for remission
[19]. The American College of Neuropsychopharmacology
(ACNP) recommended a score of ≤7 or ≤5 [7, 20]. On the
contrary, Zimmerman et al. reported that the cutoff score
of 7 on HAM-D17 could be high [21–23], and others sup-
ported similar results [24, 25]. Zimmerman also reported
HAM-D17
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Fig. 2 Scatter plot between HAM-D17 and MCS scores
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that remitters (HAM-D17 ≤ 7) had heterogeneity in their
symptoms and that the lower cutoff could be more
suitable for remission if patients’ social functionality was
considered [21–23]. Similar results were observed in the
Montgomery Åsberg Depression Rating Scale (MADRS)
[26], where patients with depression having lower scores
(≤4 vs 5–9) appeared to have better global functioning
[27]. Romera et al. proposed a similar suggestion based on
the Social and Occupational Functioning Assessment
Scale [28, 29]. A similar result was reported for functional-
ity [30]. Furukawa et al. reported that this gap was due to
the fact that functional recovery occurs after clinical re-
covery [31]. In addition, for the two scores of STAI, the
differences based on the cutoff scores of HAM-D17 (≥5
and ≤4) indicated recovery from anxiety at this level as
well. The present study investigated the relationship
between depression and HRQOL which may have con-
tributed as a reference for psychotherapeutic interven-
tions. However, it revealed the need of further studies
in this field.
Given this literature, the identification of a cutoff score
of ≤4 in our study is consistent. A 3-point gap between
the re-estimated cutoff score of ≤4 and the traditional
cutoff score of ≤7 was observed. This might imply that
the recovery of HRQOL lags behind that of depressive
symptoms (HAM-D17), and that additional time is
required for patients’ SF and QOL to reflect their HAM-
D17 score. Moreover, the assessment of patients’ func-
tional status is vital for precise estimation of QOL. In
this regard, a “cutoff value of ≤4 for HAM-D17” is not
inconsistent with this suggestion and also supports the
propositions of Zimmerman and others.
Limitations in our approach should be noted. First,
the analysis of the present study was performed retro-
spectively based on a specific population with clear
limitations; however, the intent-to-treat method was
used. Data might be biased because of our post hoc
approach. In addition, the interpretation of the results
of this study could not be applied to other conditions,
countries, species, prescription, dietary, climate, or
culture either simply or directly. These factors should
be considered in the context of the respective treat-
ment. We expect that these limitations will be remed-
ied in a future study.
Second, the clinical course of patients with depression
could have been influenced by the prescription of parox-
etine. The data for the clinical course for assessment
Table 1 Results of ROC-AUC obtained by multivariate logistic
regression
HAM-D17 Cut-off value ROC-AUC 95% Confidence
Interval
Selected Scores
of HRQOL
1 0.868 0.813–0.942 BP, VT
2 0.854 0.799–0.909 BP,VT,SF,RE
3 0.828 0.779–0.877 VT,SF,RE
4 0.848 0.808–0.887 BP,SF,RE,MH
5 0.864 0.831–0.898 PF,BP,VT,SF,RE,MH
6 0.852 0.819–0.885 PF,VT,SF,RE,MH
7 0.837 0.803–0.870 PF,VT,SF,RE,MH
8 0.844 0.813–0.875 PF,BP,VT,SF,RE,MH
9 0.837 0.806–0.868 PF,BP,VT,SF, RE,MH
10 0.834 0.803–0.864 PF,BP,SF,RE,MH
11 0.836 0.806–0.866 PF,BP,VT,SF,RE,MH
12 0.830 0.800–0.860 PF,BP,SF,RE,MH
13 0.820 0.789–0.850 PF,BP,SF,RE,MH
14 0.825 0.795–0.855 PF,BP,SF,RE,MH
15 0.820 0.790–0.850 PF,BP,RE,MH
16 0.813 0.782–0.843 PF,BP,SF,RE,MH
17 0.794 0.762–0.826 PF,BP,SF,RE,MH
18 0.790 0.758–0.822 PF,BP,RE
19 0.793 0.761–0.825 PF,BP,SF,RE
20 0.789 0.756–0.823 PF,SF,RE
21 0.792 0.758–0.826 PF,SF,RE
22 0.779 0.732–0.817 PF,RE
23 0.773 0.733–0.813
Abbreviation: HRQOL health-related quality of life, PF physical functioning,
RP role physical, BP bodily pain, GH general health perceptions, VT vitality,
SF social functioning, RE role-emotional, MH mental health
The multivariate logistic regression with the HAM-D17 score as a dependent
variable and with each of the eight domain scores of HRQOL (SF-36) as
independent variables was conducted, and the maximal ROC-AUC of 0.864
was obtained. In addition, based on the cutoff value, by converting the
HAM-D17 score into the binominal form of “0 or 1,” a multivariate analysis with
HAM-D17 as a dependent variable and with each of the eight HRQOL domain
scores (SF-36) as binominalized independent variables was performed. Then,
the significantly (p < 0.05) associated scores of the eight HRQOL domains
(SF-36) were identified. Specifically, after converting this cutoff score of
HAM-D17 into the binominal form of “0 or 1” for HAM-D17 scores of ≥5 and
≤4, the domain scores of PF, BP, VT, SF, RE, and MH are significantly negatively
correlated with HAM-D17
Table 2 Spearman’s ρ among HAM-D17 and subscores of HRQOL
PCS MCS PF RP BP GH VT SF RE MH
HAM-D17 −0.3732 −0.6890 −0.4656 −0.4542 −0.3700 −0.5325 −0.6891 −0.5488 −0.5813 −0.7049
(p < 0.001)
Abbreviations: PCS Physical component summary, MCS Mental component summary, PF physical functioning, RP role physical, BP bodily pain, GH general health
perceptions, VT vitality, SF social functioning, RE role emotional, MH mental health
The Spearman’s ρ of the HRQOL subscores with HAM-D17 are presented. All HRQOL subscores (SF-36) have a significantly negative correlation with HAM-D17
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were not obtained in a series of patients undergoing a
natural course of depression without drug (drug-naïve
patients with depression). At the very least, a pro-
spective observational study under prescription is
needed.
Third, the sample (n = 722) in this study did not
comprise completely independent data, because there
are several observations for most patients (n = 217).
The lack of independence of the sample data set
might affect the value of the cutoff score for HAM-
D17. However, randomly obtained data are considered
less meaningful in determining the turning point in
the clinical course of depression. Thus, this trade-off
might be necessary.
Fourth, for the results of the logistic regression of
HRQOL, the level of reproducibility for the selection of
the six subscores of PF, BP, VT, SF, RE, and MH that
were negatively correlated with HAM-D17 is unclear. In
addition, to identify specifically associated symptoms
with the HAM-D17 scores around 4–5 points (HAM-
D17 cutoff values of ≥5 or ≤4), six symptoms cover
almost the entire score of the HRQOL. Focusing on
specific domain scores of QOL might not always provide
consistent information.
Fifth, the entire data set is dependent on Japanese
characteristics, which could be heterogeneous and
could also introduce unexpected biases or tendencies
in the results. Specific geographic locality and popula-
tion are necessary tradeoffs in research. Therefore,
any generalization from these results should be used
with caution.
Additional investigations using more rigorous method-
ology in future studies to confirm these findings will be
necessary.
Conclusions
The cutoff value for HAM-D17 score of less than or
equal to 4 (≤4) was one of the candidates for the remis-
sion of depression if HRQOL recovery is considered.
The recovery of social function and performance are
equally important for patients with depression for the
remission of depressive symptoms.
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